Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. TCA Cellular Therapy, LLC
WARNING LETTER
•TCA Cellular Therapy, LLC•March 31, 2011

TCA Cellular Therapy, LLC – FDA Warning Letter, Mar 31, 2011

Record Details

An FDA inspection of TCA Cellular Therapy, LLC (TCA) from February 22 to March 31, 2011, revealed significant violations of regulations governing investigational new drugs (21 CFR Part 312) and human cells, tissues, and cellular and tissue-based products (HCT/Ps) (21 CFR Part 1271). TCA, acting as a sponsor and biological drug product manufacturer, failed to ensure investigations were conducted according to investigational plans and adequately monitor ongoing studies. Specific deficiencies included administering autologous investigational products to individuals not enrolled in IND studies, some while INDs were on clinical hold, and administering allogeneic cells when INDs were limited to autologous use. The firm also initiated clinical investigations without an effective IND or submitting required protocol amendments for new indications, including treating underage subjects. Furthermore, TCA administered investigational products in violation of clinical holds. For allogeneic HCT/Ps, TCA failed to determine donor eligibility through proper screening and testing for relevant communicable disease agents, including Treponema pallidum, HTLV types I and II, and Cytomegalovirus. The FDA deemed TCA's April 19, 2011, response to the Form FDA 483 inadequate. TCA must provide written documentation of corrective actions within fifteen business days to address these serious violations concerning human subject protection and communicable disease prevention, or face further regulatory action.

Company
TCA Cellular Therapy, LLC
Inspection date
March 31, 2011
Product type
Biologics
Office
Center for Biologics Evaluation and Research
Person
  • Mary A. Malarkey (Director - - Ex-FDA)
View Company Profile

ID · dafb299c-fcc7-42c8-a909-e222cd61d5d0

Violation Codes10
21 CFR 312.2021 CFR 312.3021 CFR 312.4021 CFR 312.42(a)21 CFR 312.5021 CFR 312.56(a)21 CFR 1271.50(a)21 CFR 1271.7521 CFR 1271.8021 CFR 1271.85

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore TCA Cellular Therapy, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.